- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05565651
Retrospective Study of Intestinal Microbiota in Association With Diabetes
Retrospective Study for the Characterization of the Intestinal Microbiota in Association With Pathologies and Diet in the Italian Population
The microbiota interacts with several human organs and influences the physiological process in the host. The predominant Phyla of species in the gut microbiota are Bacteroidetes (B) and Firmicutes (F), accounting for 60-80%, and Proteobacteria (P) and Actinobacteria (A) in minority. When some of the bacterial Phyla species are unbalanced, the pathological state of dysbiosis occurs. A laboratory index used for clinical analyzes is the F / B ratio <0.8, which characterizes an intestinal dysbiotic state.
Many causes can affect the intestinal microbiota, thus altering it in a dysbiotic state, first of all the diet. In fact, dysbiosis can be characterized both by the severity with which it manifests itself and is also distinguished in putrefactive and fermentative dysbiosis.
Furthermore, the variation in the "normal" percentages of the Phyla is also related to some pathological alterations.
The aim of this study will be to monitor the population and heterogeneity of the microbiota in the Italian population. Knowing the complex implications of dysbiosis and the extensive data on it, this study will want to detail the state of the gut microbiota in the previously indicated population, focusing attention on peculiar profiles that could reflect a pathogenic spectrum or metabolic disturbances.
The study aims to investigate the diffusion and state of the microbiota in the Italian territory and if it occurs in association with certain pathologies and / or diet.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Roma
-
Guidonia, Roma, Italy, 00012
- Lifebrain Cerba Healthcare laboratory network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged between 16 and 80 years old,
- Patients with completed questionnare
- Dysbiosis symptoms
Exclusion Criteria:
- Under 16 years old,
- over 80 years old,
- patients misidentified
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Outcome percentage Phyla
Time Frame: 2020-2022
|
Change in the percentage of Proteobacteria in type 2 diabetic patients
|
2020-2022
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8/14/2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysbiosis Symptoms Linked to Pathology
-
Experimental and Clinical Research CenterEnrolling by invitationGut Microbiota Dysbiosis and NutritionGermany
-
Jagiellonian UniversityCompletedMicrobiota, Cesarean Section, Probiotics, Dysbiosis
-
Copenhagen University Hospital, HvidovreCompletedTransplantation | Vaginal Dysbiosis | Vaginal MicrobiomeDenmark
-
Mucosa Innovations, S.L.Universidad de GranadaActive, not recruiting
-
Centre Hospitalier Universitaire DijonCompletedSubretinal Haematoma Linked to AMDFrance
-
International Centre for Diarrhoeal Disease Research...Bill and Melinda Gates FoundationRecruitingEnvironmental Enteric Dysfunction | Gut Microbiota DysbiosisBangladesh
-
National Taiwan University HospitalRecruitingGut Dysbiosis for TMAO Production From L-carnitine ConsumptionTaiwan
-
Persephone BiosciencesActive, not recruiting
-
Sophie Bucher Della TorreUniversity Hospital, GenevaActive, not recruiting
-
University of California, DavisCompleted
Clinical Trials on Fecal microbiota analysis
-
Ziv HospitalUnknown
-
The University of Texas Health Science Center,...TerminatedRecurrent C. Difficile InfectionUnited States
-
The Second Hospital of Nanjing Medical UniversityRecruiting
-
Madhusudan (Madhu) Grover, MBBSRecruiting
-
Medical University of GrazBristol-Myers SquibbTerminatedMalignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota TransplantationAustria
-
Chinese University of Hong KongActive, not recruitingIrritable Bowel Syndrome | Fecal Microbiota TransplantationHong Kong
-
The First Affiliated Hospital of Nanchang UniversityCompletedAcute Pancreatitis | Intestinal Bacteria Flora Disturbance | Fecal Microbiota Transplantation | Intestinal DysfunctionChina
-
University Hospital, GhentResearch Foundation FlandersRecruitingResistance BacterialBelgium
-
Jinling Hospital, ChinaUnknown
-
Lawson Health Research InstituteTerminatedAutoimmune Diseases | Relapsing Multiple SclerosisCanada